… ’ (IGF-1R) antagonist cixutumumab did result in improved … performed solely in relapsed or
metastatic NSCLC, but failed to … The ‘insulin-like growth factor receptor 1’ (IGF-1R) is frequently …

… progressed to an advanced stage in many cases (2). Most … antibodies were purchased from
Cell Signaling Technology, Inc. … of pancreatic ductal adenocarcinoma (PDAC), Gemcitabine …

… Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1
signaling in metastatic … of gemcitabine, erlotinib, and cixutumumab versus gemcitabine …

… (EGFR) and fibroblast growth factor receptor 1 (FGFR1) serve … in a phase II trial of second-line
paclitaxel plus cixutumumab in … In a phase III trial of erlotinib in combination with dCRT in …

… , et al., Dual blockade of epidermal growth factor receptor and insulin-like growth factor
receptor-1 signaling in metastatic … of gemcitabine, erlotinib, and cixutumumab versus gemcitabine …

… extrinsic growth factors or insensitivity to anti-growth signals. … CRC and pancreatic ductal
adenocarcinoma (PDAC) (which … The insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) …

… Cixutumumab did not show improved outcome in phase I/II … reduction of liver metastases
of lung and colon carcinoma but also … 4 times during the 28-day cycles in addition to erlotinib. …

… pancreatic cancer initiation, progression and metastasis, … -IGF1 antibodies ganitumab and
cixutumumab 40, have also … combinational erlotinib treatment over gemcitabine alone 41. …

… aspects of tumor progression, including metastasis and therapy resistance. … erlotinib,
conferring a mean survival benefit of ~2 weeks in combination with gemcitabine over gemcitabine …

… or distant metastatic disease (eg, a bone metastasis), we use … phase I-II trial of the anti-IGF1R
antibody cixutumumab … EGFR inhibitor erlotinib in combination with gemcitabine was …